The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Multi-stakeholder initiative highlights inclusive sports pathways, honours neurodivergent athletes, and calls for systemic reforms
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
_and_Dr__D_Nageshwar_Reddy_(AIG_Hospitals)_256_384.jpg)
The collaboration is designed to improve clinical outcomes, reduce procedural risks, and expand access to advanced image-guided treatments across a growing range of conditions
Move comes amid rising regulatory pressures
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery
Subscribe To Our Newsletter & Stay Updated
